MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials
Related News

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma, Non-Hodgkin
Interventions
Biological: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
First Posted Date
2009-10-16
Last Posted Date
2017-01-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
77
Registration Number
NCT00996996

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Phase 2
Completed
Conditions
Lymphoma, Non-Hodgkin
Interventions
Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
First Posted Date
2009-10-16
Last Posted Date
2016-11-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
43
Registration Number
NCT00996593

Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2009-10-16
Last Posted Date
2017-05-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
7641
Registration Number
NCT00995995

Study to Assess Cardiac Conduction of GSK1349572

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: GSK1349572 250 mg
Drug: Placebo Suspension
First Posted Date
2009-10-16
Last Posted Date
2010-01-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
42
Registration Number
NCT00996021
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

Phase 1
Completed
Conditions
Cardiovascular Disease
Interventions
First Posted Date
2009-10-16
Last Posted Date
2017-06-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
46
Registration Number
NCT00996268
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Placebo
First Posted Date
2009-10-16
Last Posted Date
2017-06-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
38
Registration Number
NCT00996671
Locations
🇦🇺

GSK Investigational Site, Melbourne, Victoria, Australia

Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom

Completed
Conditions
Influenza
Interventions
Other: Safety follow up
First Posted Date
2009-10-16
Last Posted Date
2018-01-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
9206
Registration Number
NCT00996853
Locations
🇬🇧

GSK Investigational Site, York, United Kingdom

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Phase 1
Completed
Conditions
Neoplasms, Breast
Interventions
First Posted Date
2009-10-16
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
158
Registration Number
NCT00996762
Locations
🇰🇷

GSK Investigational Site, Seoul, Korea, Republic of

Vestipitant 28-day Tolerance Study

Phase 2
Completed
Conditions
Sleep Disorders
Interventions
Drug: Placebo
First Posted Date
2009-10-09
Last Posted Date
2016-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
161
Registration Number
NCT00992160
Locations
🇩🇪

GSK Investigational Site, Hamburg, Germany

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Phase 3
Completed
Conditions
Influenza
Interventions
Biological: GSK investigational vaccine GSK2340272A
First Posted Date
2009-10-09
Last Posted Date
2019-01-31
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT00992511
Locations
🇩🇪

GSK Investigational Site, Leipzig, Sachsen, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy